Abstract
Background
Role of GLP-1 variants on basal GLP-1 levels, body weight and cardiovascular risk factors remains unclear in patients with diabetes mellitus type 2.
Objective
Our aim was to analyze the effects of rs6923761 GLP-1 receptor polymorphism on body weight, cardiovascular risk factors, basal GLP-1 levels and serum adipokine levels in naïve patients with diabetes mellitus type 2.
Design
A sample of 104 naïve patients with diabetes mellitus type 2 was enrolled in a prospective way. Basal fasting glucose, c-reactive protein (CRP), insulin, insulin resistance (HOMA), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides concentration, basal GLP-1, HbA1c and adipokines (leptin, adiponectin, resistin) levels were determined. Weights, body mass index, waist circumference, fat mass by bioimpedance and blood pressure measures were measured.
Results
Forty-nine patients (47.1 %) had the genotype GG and 55 (52.9 %) diabetic subjects had the next genotypes; GA (44 patients, 42.3 %) or AA (11 study subjects, 10.6 %) (second group). In A allele carriers, basal GLP-1 levels were higher than non-carriers (2.9 ± 2.1 ng/ml; p < 0.05). No differences were detected between both genotype groups.
Conclusion
Our cross-sectional study revealed an association between the rs6923761 GLP-1 receptor polymorphism (A allele carriers) and basal GLP-1 levels in naïve patients with diabetes mellitus type 2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BMI:
-
Body mass index
- GLP-1:
-
Glucagon-like peptide
- GLP-1-R :
-
Glucagon-like peptide 1 receptor
- HOMA:
-
Homeostasis model assessment
- CRP:
-
C-reactive protein
References
Kieffer TJ, Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876–913
Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes/Metab Res Rev 18:430–441
Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968–2978
Thorens B (1992) Expression cloning of the pancreatic beta-cell receptor for the gluco-incretin hormone glucagon peptide-1. Proc Natl Acad Sci USA 89:8641–8645
Scrocchi LA, Brown N, MacLusky N (1996) Glucose intolerance but normal satiety in mice with a null mutation in the GLP-1R gene. Nat Med 2:1254–1258
Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A (2004) Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract 66:63–69
Beinborn M, Worrall CI, McBride MW, Kopin AS (2005) A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 130:1–6
Sathananthan A, Dalla C, Micheletto F, Zinsmeister A, Camilleri M, Giesler P (2010) Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes Care 33:2074–2076
Matsuda M, Shimomura I, Sata M (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491
Kumada M, Kihara S, Sumitsuji S (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89
Steppan CM, Bailey ST, Bhat S (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312
Adipocytokines MY (2005) Emerging therapeutic targets. Curr Atheroscler Rep 7:58–62
Mataix J, Mañas M (2003) Tablas de composición de alimentos españoles. Ed: University of Granada
Duart MJ, Arroyo CO, Moreno JL (2002) Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 40:1161–1167
Mathews DR, Hosker JP, Rudenski AS et al (1985) Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–414
Pfutzner A, Langefeld M, Kunt T et al (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin lab 49:571–576
Meier U, Gressner M (2004) Endocrine regulation of energy metabolis: review of pathobiochemical and clinical chemical aspects of leptin, Ghrelin, adiponectin, and resistin. Clin Chem 50:1511–1525
Suominen P (2004) Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 50:219–221
Adam TCM, Jocken J, Westerterp-Plantenga MS (2005) Decreased glucagon like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 13:710–715
Lukaski H, Johnson PE (1985) Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 41:810–817
Stolerman ES, FLorez JC (2009) Genomics of type 2 diabetes mellitus implications for the clinician. Nat Rev Endocrinol 5:429–436
Scrocchi LA, Marshall BA, Cook SM, Brubaker DJ (1998) Identification of GLP-1 actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632–639
Abdul-Ghani MA, Williams K, Kanat M, Altuntas Y, DeFronzo RA (2014) Insulin vs GLP-1 analogues in poorly controlled type 2 diabetic subjects on oral therapy: a meta-analysis. J Endocrinol Invest 36:168–173
Conflict of interest
No conflicts of interest have been declared by all authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Luis, D.A., Aller, R., Izaola, O. et al. Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients. J Endocrinol Invest 38, 143–147 (2015). https://doi.org/10.1007/s40618-014-0161-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-014-0161-y